| Primary information |
|---|
| sequence ID | Seq_5818 |
| Peptide sequence | NVHSAGAAGSRMNFRPGVLSS |
| CancerPDF_ID | CancerPDF_ID62, CancerPDF_ID1071, |
| PMID | 16896061,16395409 |
| Protein Name | PRO1851(ITIH4 splice variant),PRO1851(ITIH4 splice variant) |
| UniprotKB Entry Name | ITIH4_HUMAN,NA |
| Fluid | Serum,Serum |
| M/Z | 2115.01,2115.01 |
| Charge | 1,1 |
| Mass (in Da) | 2115.04,NA |
| fdr | NA,NA |
| Profiling Technique | MALDI-TOF,MALDI-TOF |
| Peptide Identification technique | Q/TOF MS/MS,Q/TOF/TOF and LC-MS/MS |
| Quantification Technique | NA,NA |
| Labelled/Label Free | Label Free,Label Free |
| FDR | NA,less than 1 “5 |
| CancerPDF_ID | CancerPDF_ID62, CancerPDF_ID1071, |
| p-Value | 1.00E-05,5.82E-18 |
| Software | MASCOT,MASCOT (v 2.0.04 for Windows) |
| Length | 21,21 |
| Cancer Type | Metastatic thyroid carcinomas,"Advanced Prostate, Breast and Bladder cancer" |
| Database | NCBI refseq Protein Database,NCBI refseq Protein Database |
| Modification | NA,NA |
| Number of Patients | 40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy in training test set, In validation set 41 independent serum samples from patients with advanced prostate cancer (prostate 2 [PR2])" |
| Regulation | NA,"Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =3.22, 12.23 and 10.61 in prostate, bladder and breast cancer respectively" |
| Validation | Independent validation,Independent validation |
| Sensitivity | 95% on independent dataset,97.5% for multiclass and 100 % for binary classification system on independent validation dataset |
| Specificity | 95% on independent dataset,NA |
| Accuracy | NA,97.5 % on validation dataset |
| Peptide Atlas | NA |
| IEDB | |